久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

USEUROPEAFRICAASIA 中文雙語(yǔ)Fran?ais
China
Home / China / Business

Medicine trade tops $100b in 2015

By Wang Wen | China Daily | Updated: 2016-02-08 16:03

China's trade in medicines hit an all-time high of $102 billion last year.

The latest figures from the China Chamber of Commerce for Import and Export of Medicines and Health Products show the value was a 4.73 percent increase on 2014, and this year total export-import volumes are expected to rise again, by 3 to 5 percent.

Xu Ming, the chamber's deputy director, called the overall growth "healthy and stable", adding, however, that the Chinese export market had slowed.

Medicine imports were worth $46.2 billion, up 7.3 percent, while exports grew a slower 2.7 percent to $56.4 billion.

"That import growth indicates the Chinese domestic market has huge potential, as it is now the second-largest globally after the United States," said Xu.

The weaker export figures were largely indicative of an ongoing global economic slowdown, Xu said, and coupled with a weaker yuan, they put China on the back foot as an international medicine supplier.

Exports to the US performed well, even though some other main markets dropped. Volumes to the US grew 7.72 percent compared with the previous year and it is now China's second-largest medicine export market after Europe, where demand dropped 0.22 percent.

Xu remains positive that Chinese companies are making strong headway in their moves to expand trade abroad.

Some have been expanding through investment and merger, which is often a more complicated route than simply selling their products directly.

"It's astonishing how some Chinese companies have performed so well in overseas investments," Xu said.

One of the sector's most significant developments in 2015 was by a consortium led by Shanghai Fosun Pharmaceutical Group Co Ltd, which bought Ambrx Inc, a US biotechnology company focusing on molecular medicine.

The acquisition group also involved HOPU Jinghua (Beijing) Investment Consultancy Co Ltd, China Everbright Ltd's healthcare fund, and Wuxi PharmaTech, and the purchase included some valuable global biotechnology.

Fosun Pharma's Chairman Chen Qiyu said the acquisition would "produce a dramatic synergistic effect on Fosun's current development system".

Ambrx is now expected to build a global products development center in China, Chen said.

Other moves saw Chinese companies signing agreements with foreign companies to sell their products overseas.

Jiangsu Heng Rui Medicine Co Ltd, for instance, authorized US-based pharmaceutical company Incyte Corp to develop and sell its PD-1 antibody product outside China in September, with the Delaware firm paying $795 million for the right.

wangwen@chinadaily.com.cn

 

Editor's picks
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 456主播喷水在线观看 | 无限观看社区在线视频 | 亚洲网址在线 | 亚洲综合网址 | 99精品热女视频专线 | 久久久久久久久中文字幕 | 欧美激情欧美狂野欧美精品免费 | 国产一级一级 | 毛片免费看网站 | 精品国产a| 91精品久久国产青草 | 99国内精品久久久久久久 | 国产综合在线播放 | 怡红院亚洲红怡院天堂麻豆 | 久久久久亚洲精品影视 | 免费一级网站免费 | 亚洲系列 | 美美女下面被cao爽 美女131爽爽爽做爰中文视频 | 亚洲精品日韩专区在线观看 | 美女又黄又免费 | 亚洲一区天堂 | 午夜影院黄色片 | 国产综合在线观看视频 | 国产成人亚洲精品无广告 | 国产成人高清 | 国产的一级毛片完整 | 女人精aaaa片一级毛片女女 | 久久久亚洲国产精品主播 | 日本一区二区高清不卡 | 国产美女一区精品福利视频 | 婷婷色综合久久五月亚洲 | 国产不卡视频在线观看 | 成人久久18免费网站游戏 | 久久不色 | 亚洲男人天 | 久久国产精品久久久久久久久久 | 国产一级片免费观看 | 国产精品亚洲一区二区三区在线观看 | 久久亚洲国产精品五月天 | 亚洲精品一区二区三区在线看 | 亚洲成人在线免费观看 |